Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Inhibition of protein-protein interactions among tubulins in vitro and in cellulo using C-terminal-binding nanoparticles.

Created on 06 Jul 2026

Authors

Mansi Sharma, Yan Zhao

Published in

RSC advances. Jul 03, 2026. Epub Jul 03, 2026.

Abstract

Protein-protein interactions (PPIs) are fundamental to cellular function, yet selectively inhibiting them remains a significant challenge. This difficulty arises because PPI interfaces involve surface areas (1000-5000 Å2) significantly larger than those involved in small-molecule ligand recognition. Here, we report the development of molecularly imprinted nanoparticles (MINPs) designed to target the disordered C-terminal tails (CTTs) of α- and β-tubulins. By modulating hydrogen-bonding functional monomers and cross-linkers, we tuned the MINP binding properties to achieve either dual α- and β-tubulin affinity or high selectivity for a single isoform. A nonselective MINP was found to outperform its more selective counterparts, likely by maximizing target occupancy and inducing steric clashes across the microtubule lattice. This dense molecular recognition leads to potent microtubule disruption, G2/M phase arrest, and apoptosis in MDA-MB-231 breast cancer cells. These findings demonstrate that intrinsically disordered protein regions like CTTs are viable targets for PPI regulation.

PMID:
42405052
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement